Table 4.
Univariate analysis of risk factors for CMV IgG positive in patients with inflammatory bowel disease
| |
CMV IgG+/IgG- |
|||||
|---|---|---|---|---|---|---|
| |
UC |
CD |
||||
| (139/50) | (33/4) | |||||
| Age |
Number |
P value |
OR (95% CI) |
Number |
P value |
OR (95% CI) |
| ≤50 ys |
107/32 |
0.074 |
1.881 (0.934 ~ 3.786) |
21/3 |
1.000 |
0.583 (0.054 ~ 6.251) |
| >50 ys |
32/18 |
|
|
12/1 |
|
|
| Sex |
|
|
|
|
|
|
| male |
82/27 |
0.540 |
1.225 (0.639 ~ 2.349) |
21/2 |
0.625 |
1.750 (0.218 ~ 14.069) |
| female |
57/23 |
|
|
12/2 |
|
|
| Smoking |
|
|
|
|
|
|
| yes |
32/13 |
0.672 |
0.851 (0.404 ~ 1.793) |
9/0 |
0.554 |
N/A |
| no |
107/37 |
|
|
24/4 |
|
|
| Drinking |
|
|
|
|
|
|
| Yes |
53/22 |
0.467 |
0.784 (0.407 ~ 1.510) |
10/2 |
0.582 |
0.435 (0.053 ~ 3.536) |
| no |
86/28 |
|
|
23/2 |
|
|
| Diet composition |
|
|
|
|
|
|
| vegetarian food |
14/4 |
0.883 |
1.288 (0.403 ~ 4.115) |
3/3 |
0.010* |
0.033 (0.003 ~ 0.429) |
| mixed food |
125/46 |
|
|
30/1 |
|
|
| Fever |
|
|
|
|
|
|
| yes |
26/6 |
0.278 |
1.687 (0.650 ~ 4.379) |
4/0 |
1.000 |
N/A |
| no |
113/44 |
|
|
29/4 |
|
|
| Hemoglobin (G/L) |
|
|
|
|
|
|
| ≤70 |
7/2 |
1.000 |
1.273 (0.255 ~ 6.341) |
0/0 |
- |
N/A |
| >70 |
132/48 |
|
|
33/4 |
|
|
| Albumin (G/L) |
|
|
|
|
|
|
| ≤35 |
16/5 |
0.771 |
1.171 (0.405 ~ 3.381) |
11/2 |
0.602 |
0.500 (0.062 ~ 4.040) |
| >35 |
123/45 |
|
|
22/2 |
|
|
| Disease severity |
|
|
|
|
|
|
| mild and moderate |
120/48 |
0.109 |
0.263 (0.059 ~ 1.173) |
26/4 |
0.570 |
N/A |
| severe |
19/2 |
|
|
7/0 |
|
|
| Location |
|
|
|
|
|
|
| distal colitis |
108/32 |
0.058 |
1.960 (0.971 ~ 3.955) |
|
|
|
| pancolitis |
31/18 |
|
|
|
|
|
| ileal |
|
|
|
7/1 |
0.219 |
N/A |
| Colonic |
|
|
|
14/0 |
|
|
| ileocolon |
|
|
|
12/3 |
|
|
| Treatment |
|
|
|
|
|
|
| ASA/SASP |
119/30 |
<0.001* |
3.967 (1.897 ~ 8.296) |
18/2 |
1.000 |
1.200 (0.150 ~ 9.570) |
| corticosteroids |
38/9 |
0.190 |
1.714 (0.761 ~ 3.861) |
8/0 |
0.557 |
N/A |
| immunosuppressant | 5/0 | 0.328 | N/A | 2/0 | 1.000 | N/A |
CMV, cytomegalovirus; UC, ulcerative colitis; ASA, aminosalicylic acid; SASP, salicylazosulfapyridine.
*indicate significant difference.